IFEC   20925
INSTITUTO DE FARMACOLOGIA EXPERIMENTAL DE CORDOBA
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
IGF-1 GENE THERAPY IN AN EARLY MODEL OF PARKINSON´S DISEASE
Autor/es:
FALOMIR LOCKHART E; HEREÑÚ C.; HERRERA M.; BELLINI MJ; DOLCETTI FRANCO
Lugar:
Paris
Reunión:
Congreso; ISN-ESN Biennial Meeting; 2017
Resumen:
Backgound: Insulin-like growth factor-1 (IGF-1) is an endogenous peptide transported across the blood brain barrier that is protective in several brain injury models, including in an animal model of Parkinson?s disease (PD).Objectives: To determine in an experimental model of the neuropathology if IGF-1 gene therapy could: 1) improve the cognitive dysfunctions and 2) induce changes in the neuronal activity of the affected brain areas.Methods: Male Wistar rats were bilaterally injected in CPu with either the neurotoxic 6-hydroxydopamine (6OHDA rats), or vehicle (SHAM rats) as controls. Then they were divided into 6 experimental groups according to the gene therapy with adenovirus in hippocampus: G1) SHAM (vehicle-vehicle), G2)6OHDA (neurotoxic-vehicle), G3) SHAM-RAd-DS-Red, G4) SHAM-RAd-IGF-1, G5) 6OHDA-RAd-DS-Red, G6) 6OHDA-RAd-IGF-1. At 3 weeks post lesion with 6OHDA and injection with adenovirus the animals were tested for spatial memory with Y-maze test and for locomotor activity. At the end of the study the rats were perfused, the brains fixed and immunohistochemistry performed for TH and IGF-1. All data were compared by 2-way ANOVA (p < 0.05 considered as statistically significant).Results: 6OHDA causes cognitive deficits in G2 compare to G1 (p > 0.05) indicated by a decreased in spontaneous alternation percentage. This effect could not be attributed to decreased motor activity, because the number of arm entries was not significantly changed and neither the number of cm performed after amphetamine administration. This effect was partially reverted with IGF-1 overexpression in G6 respected to G5 (p > 0.05). There were no significant changes in G2 respect G5 and in G1 respected to G3 and G4. Preliminary results showed that IGF-1 gene therapy induce an increase in TH expression in the nigrostriatal pathway.Conclusions: our results suggest that IGF-1 could be an important neuroprotective molecule against neurodegeneration. Its effect on neuronal activity could explain in part the improvement in the cognitive symptoms that we observed in this animal model of PD